UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005352
Receipt number R000006342
Scientific Title A phase 2 study of dasatinib-combined chemotherapy in patients with relapsed Philadelphia chromosome-positive acute lymphoid leukemia.
Date of disclosure of the study information 2011/04/01
Last modified on 2012/01/03 00:33:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A phase 2 study of dasatinib-combined chemotherapy in patients with relapsed Philadelphia chromosome-positive acute lymphoid leukemia.

Acronym

A phase 2 study of dasatinib-combined chemotherapy in patients with relapsed Philadelphia chromosome-positive acute lymphoid leukemia.

Scientific Title

A phase 2 study of dasatinib-combined chemotherapy in patients with relapsed Philadelphia chromosome-positive acute lymphoid leukemia.

Scientific Title:Acronym

A phase 2 study of dasatinib-combined chemotherapy in patients with relapsed Philadelphia chromosome-positive acute lymphoid leukemia.

Region

Japan


Condition

Condition

Philadelphia chromosome positive acute lymphoblastic leukemia

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To find out the efficacy and safety of dasatinib-combined chemotherapy for patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Complete hematological remission rate in induction therapy

Key secondary outcomes

Hematological remission rate
Complete cytogenetical remission rate
Major molecular remission rate
Overall survival rate at 1 year
Treatment related toxicity


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Dasatinib combined chemotherapy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

1. Relapsed Ph-chromosome positive acute lymphoblastic leukemia.
2. PS 0-2 (ECOG)
3. Adequate hepatic, renal, pulmonary and cardiac function
4. No active gastro-intestinal bleeding
5. No evidence of CNS relapse
6. Written informed consent

Key exclusion criteria

1. Severe comorbidity
(infection, lung disease, hypertension, heart failure, diabetes mellitus)
2. Recent history of ischemic heart disease
3. Other active neoplasms
4. Pregnant and/or lactating woman

5. Psychological disorders

6. Positive HBs antigen and/or anti-HIV antibody
7. Received allogeneic stem cell transplantation within 100 days
8. Receiving immunosuppressive agents (cyclosporine, tacrolimus)

Target sample size

19


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shuichi Mizuta

Organization

Fujita Health University

Division name

Department of Hematology

Zip code


Address

1-98 Dengakugakubo, Kutsukake-cho, Toyoake

TEL

0562-93-9243

Email



Public contact

Name of contact person

1st name
Middle name
Last name Shuichi Mizuta

Organization

Fujita Health University

Division name

Department of Hematology

Zip code


Address

1-98 Dengakugakubo, Kutsukake-cho, Toyoake

TEL

0562-93-9243

Homepage URL

http://www.jalsg.jp/03/touroku.html

Email

mizuta@mb.ccnw.ne.jp


Sponsor or person

Institute

Japan Adult Leukemia Study Group

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labor and Welfare

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)

NPO JALSG supporting organization


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

JALSG参加の施設およびその関連病院とする。また更新される場合があるのでJALSGホームページに記載のある最新の施設を参照する。

北海道  (40都道府県)
青森県
宮城県
秋田県
山形県
福島県
栃木県
茨城県
群馬県
埼玉県
千葉県
東京都
神奈川県
新潟県
富山県
石川県
福井県
長野県
岐阜県
静岡県
愛知県
三重県
滋賀県
京都府
大阪府
兵庫県
奈良県
島根県
岡山県
広島県
山口県
香川県
愛媛県
高知県
福岡県
佐賀県
長崎県
熊本県
大分県
鹿児島県


Other administrative information

Date of disclosure of the study information

2011 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2011 Year 02 Month 24 Day

Date of IRB


Anticipated trial start date

2011 Year 04 Month 01 Day

Last follow-up date

2014 Year 03 Month 01 Day

Date of closure to data entry

2014 Year 06 Month 01 Day

Date trial data considered complete

2014 Year 07 Month 01 Day

Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 03 Month 30 Day

Last modified on

2012 Year 01 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006342


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name